SCHEMBL1553418

SCHEMBL1553418

CCOC(=O)c1c(-c2cccc(Cl)c2Cl)csc1N

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 9/20 0.64
ALDH1A1 P00352 7/20 0.60
MAPT P10636 4/20 0.60
GAA P10253 1/20 0.60
KEAP1 Q14145 1/20 0.60
HSD17B10 Q99714 5/20 0.58
HPGD P15428 1/20 0.58
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
ALOX15 P16050 3/20 0.58
TDP1 Q9NUW8 2/20 0.58
MPI P34949 1/20 0.57
USP2 O75604 1/20 0.57
MAPK1 P28482 3/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
PRKCI P41743 2/20 0.55
GRM6 O15303 1/20 0.55
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL689476 0.90 PRKCZ (0.67) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL1554267 0.82 PRKCZ (0.69) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL8290591 0.80 PRKCZ (0.71) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL18342647 0.80 ALDH1A1 (0.60) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL689530 0.80 PRKCZ (0.69) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL1553971 0.79 ALDH1A1 (0.46) PRKCZALDH1A1MAPTGAAHPGD
SCHEMBL689025 0.79 PRKCZ (0.73) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL688430 0.79 PRKCZ (0.63) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL690269 0.78 PRKCZ (1.00) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL7613063 0.78 PRKCZ (0.63) PRKCZALDH1A1MAPTGAAKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383463-B1 FUSED THIOPHENE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF CHRONIC PAIN KING PHARMACEUTICALS INC (US) 2011-04-27 EP disclosed
EP-1383463-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS INC (US) 2009-03-25 EP disclosed
US-7449490-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2008-11-11 US disclosed
US-7101905-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-09-05 US disclosed
US-20060183921-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2006-08-17 US disclosed
EP-1383463-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE King Pharmaceuticals, Inc. (US) 2004-01-28 EP disclosed
US-20030073733-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-04-17 US disclosed
WO-2002083083-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS, INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183921-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE PRKCZ 3577/4885ALDH1A1 1591/4885MAPT 1176/4885
US-20030073733-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE PRKCZ 3577/4885ALDH1A1 1591/4885MAPT 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.